The stock of Immunomedics, Inc. (NASDAQ:IMMU) is a huge mover today! About 2.91 million shares traded hands or 65.34% up from the average. Immunomedics, Inc. (NASDAQ:IMMU) has risen 12.12% since April 20, 2016 and is uptrending. It has outperformed by 7.57% the S&P500.
The move comes after 7 months positive chart setup for the $397.59M company. It was reported on Nov, 22 by Barchart.com. We have $3.80 PT which if reached, will make NASDAQ:IMMU worth $27.83 million more.
Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage
Out of 2 analysts covering Immunomedics (NASDAQ:IMMU), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Immunomedics has been the topic of 6 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Jefferies upgraded Immunomedics, Inc. (NASDAQ:IMMU) rating on Friday, May 6. Jefferies has “Buy” rating and $5 price target. As per Tuesday, June 21, the company rating was downgraded by Wells Fargo. The stock of Immunomedics, Inc. (NASDAQ:IMMU) earned “Market Perform” rating by Wells Fargo on Friday, December 4. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Thursday, October 6 by Jefferies. The stock has “Hold” rating given by Jefferies on Wednesday, July 29. The company was maintained on Tuesday, March 15 by Jefferies.
According to Zacks Investment Research, “Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.”
Insitutional Activity: The institutional sentiment decreased to 0.83 in 2016 Q2. Its down 0.19, from 1.02 in 2016Q1. The ratio turned negative, as 14 funds sold all Immunomedics, Inc. shares owned while 34 reduced positions. 27 funds bought stakes while 22 increased positions. They now own 50.90 million shares or 5.47% more from 48.26 million shares in 2016Q1.
Creative Planning owns 58,485 shares or 0% of their US portfolio. The Florida-based State Board Of Administration Of Florida Retirement System has invested 0% in Immunomedics, Inc. (NASDAQ:IMMU). Weiss Multi holds 0.01% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU) for 72,900 shares. Bancshares Of America Corp De reported 20,396 shares or 0% of all its holdings. Alliancebernstein L P has 0% invested in the company for 185,498 shares. Parametric Associate Ltd Liability Corporation has invested 0% of its portfolio in Immunomedics, Inc. (NASDAQ:IMMU). Moreover, Manufacturers Life Ins The has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 62,490 shares. Tiaa Cref Invest Management Limited Liability Company has 0% invested in the company for 386,678 shares. Balyasny Asset Mngmt Ltd holds 1.10 million shares or 0.02% of its portfolio. Blackrock Inv Ltd Liability owns 349,301 shares or 0% of their US portfolio. Moreover, Next Gp has 0.01% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 13,000 shares. Pnc Grp Incorporated has 714 shares for 0% of their US portfolio. Vanguard Grp accumulated 3.68 million shares or 0% of the stock. Moreover, Bank & Trust Of Montreal Can has 0% invested in Immunomedics, Inc. (NASDAQ:IMMU) for 440 shares. Acuta Limited Liability Corporation accumulated 4.20 million shares or 4.68% of the stock.
Insider Transactions: Since June 6, 2016, the stock had 0 insider buys, and 7 selling transactions for $5.11 million net activity. 15,000 shares were sold by MARKISON BRIAN A, worth $44,634 on Tuesday, August 23. $1.13M worth of Immunomedics, Inc. (NASDAQ:IMMU) was sold by GOLDENBERG CYNTHIA L on Friday, June 10. PAETZOLD MARY E sold $44,673 worth of stock. Stark Don C sold $29,451 worth of stock or 9,900 shares. GOLDENBERG DAVID M also sold $1.13M worth of Immunomedics, Inc. (NASDAQ:IMMU) shares.
Another recent and important Immunomedics, Inc. (NASDAQ:IMMU) news was published by Businesswire.com which published an article titled: “venBio Comments on its Recent Nomination of Four Highly-Qualified Candidates …” on November 22, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.